A study on drug innovation lag in Taiwan

Chung, Chia-Jung; Huang, Weng-Foung

doi:10.38212/2224-6614.2509

Cited by 2 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to Chung, who reported in 2006 that the NHI reimbursement price does not noticeably influence reimbursement lag in Taiwan, 6 we found the pharma‐proposed NHI reimbursement price to be significantly associated with prolonged reimbursement lag of new drugs in the non‐L group ( Table 6 ); higher budget impact significantly influenced the reimbursement lag of new drugs in the ATC group L ( Table 5 ). These findings reflect current practice.…”

Section: Discussioncontrasting

confidence: 99%

“…The average reimbursement lag in Taiwan from 1996 to 2002 was 11.7 months (~ 355 days), 6 lower than 378,458 days (median) in first‐generation NHI and days (median) under second‐generation NHI in this study ( Table 3 ). Although the reimbursement lag in Taiwan seems not to have improved over time, much has changed between these two study periods, including the introduction of health technology assessments in 2007, and the introduction of PBRS in 2013.…”

Section: Discussionmentioning

confidence: 58%

“…The NHIA drug list status and reimbursement lag substantially influence drug accessibility. In a study of drug lag in Taiwan during 1996-2002, the average reimbursement lag was 11.7 months 6 ; that study also found that the NHI reimbursement price had a negligible effect on reimbursement lag. Regrettably, no more recent studies have updated the reimbursement lag duration and its important determinants in Taiwan.…”

Section: Study Highlights What Is the Current Knowledge On The Topic?mentioning

confidence: 92%

“…New drugs in Taiwan were further categorized, according to innovativeness and efficacy vs. existing therapy: category 1 (breakthrough drugs), category 2A (drugs with moderately improved efficacy), and category 2B ("me-too" drugs). Table 1 summarizes the 10 exploratory variables incorporated into model analyses to identify factors associated with the continuous dependent variable of reimbursement lag; these were selected based on perceived relevance to the reimbursement listing process in Taiwan, 6,16 and according to previous studies 20 and expert opinion. They comprise three main groups: drug characteristics, evaluation criteria for new drug reimbursement, and PBRS policies.…”

Section: Sample Selection and Inclusion Criteriamentioning

confidence: 99%

“…Drug lag, defined as delay in approval (“marketing lag”) and/or reimbursement (“reimbursement lag”) of new drugs, 6 is a potentially significant barrier to patient access. Therefore, marketing authorization and drug reimbursement are key hurdles to overcome in expediting patient access to new medicines.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Reimbursement Lag of New Drugs Under Taiwan's National Health Insurance System Compared With United Kingdom, Canada, Australia, Japan, and South Korea

Shih

Liao

Chen

et al. 2020

Clinical Translational Sci

View full text Add to dashboard Cite

Drug lag—delayed approval or reimbursement—is a major barrier to accessing cutting‐edge drugs. Unlike approval lag, reimbursement lag is under‐researched. We investigated the key determinants of reimbursement lag under Taiwan National Health Insurance (NHI), and compared this lag with those in the United Kingdom, Canada, Australia, Japan, and South Korea. Using retrospective data on 190 new NHI‐reimbursed drugs from 2007 to 2014, we studied reimbursement lag in Taiwan vs. other countries, and investigated associated factors using generalized linear models (GLMs). The median reimbursement lags during before (“first‐generation”) and after (“second‐generation”) NHI drug reimbursement scheme in Taiwan were 378 and 458 days, respectively. The “first‐generation” lag was shorter only than that in South Korea, whereas the “second‐generation” lag only exceeded those of the United Kingdom and Japan. In GLM models, higher drug expenditure and the introduction of the “second‐generation” NHI were two statistically significant parameters associated with reimbursement lag among antineoplastic and immunomodulating agents. For other drug classes, the reimbursement price proposed by pharmaceutical companies and use of price‐volume agreements were two statistically significant parameters associated with longer reimbursement lags. The current reimbursement lag in Taiwan is longer than 1 year, but only longer than those of the United Kingdom and Japan. The determinants differ between drug categories. A specific review process for antineoplastic and immunomodulating drugs may expedite reimbursement. There is a clear need for systematic data collection and analysis to ascertain factors associated with reimbursement lag and thereby inform future policy making.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 58%

Section: Study Highlights What Is the Current Knowledge On The Topic?mentioning

confidence: 92%

Section: Sample Selection and Inclusion Criteriamentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Reimbursement Lag of New Drugs Under Taiwan's National Health Insurance System Compared With United Kingdom, Canada, Australia, Japan, and South Korea

Shih

Liao

Chen

et al. 2020

Clinical Translational Sci

View full text Add to dashboard Cite

show abstract

Antineoplastic drug access in Thailand

Saerekul

View full text Add to dashboard Cite

The access to antineoplastic drugs has been a major concern affecting cancer patients on treatment plan as well as treatment costs. This descriptive study aimed to assess and compare the situation of access to anticancer drugs between Thailand and benchmarked countries, and to explore determinants influencing the accessibility of antineoplastic drugs in Thailand. The data on drug registration information of antineoplastic medications approved during 1982 and April 2016 were acquired from websites of the drug regulatory agency of studied countries including Thailand, Singapore, Malaysia, US, UK, and EMA. The result showed that Thailand had registered 88 out of 180 active pharmaceutical ingredients (APIs) of antineoplastic listed by WHO, comparing with 130 APIs registered in USA, 119 in UK, 75 in EMA, 92 in Singapore, and 68 in Malaysia. Of 88 APIs registered in Thailand, 38 were listed under National List of Essential Medicine (NLEM) for patient access. The time lag, which was time difference between market authorization approval (MAA) date in Thailand and in the compared country, was reported that on average Thailand has anticancer drugs available in the market 37.26 months later than US, 4.52 months than UK, 12.22 months than EMA, 10.73 months than Singapore, and 6.51 months than Malaysia. Trend analysis illustrated that the market access of antineoplastic drugs has been improved overtime from 87.59 months during 1983-1990 to 23.62 months during 2007-2016. However, the longer waiting time for patient access was reported. It took 88.05 months on average for a product to be listed under the National List of Essential Medicine (NLEM) after registered in Thailand. The analysis on determinants of market access pointed that the only significant determinant explained market access of antineoplastic drugs was the novelty level. The API listed as the 2nd or 3rd me-too was found to enter Thai market faster than others of the same classification. The study concluded that market access of antineoplastic drugs in Thailand had been improved overtime and comparative with Singapore and Malaysia. It was recommended that the process for anticancer drugs to be listed under NLEM for broader patient access needed to be revised.

show abstract

A study on drug innovation lag in Taiwan

Cited by 2 publications

References 8 publications

Reimbursement Lag of New Drugs Under Taiwan's National Health Insurance System Compared With United Kingdom, Canada, Australia, Japan, and South Korea

Reimbursement Lag of New Drugs Under Taiwan's National Health Insurance System Compared With United Kingdom, Canada, Australia, Japan, and South Korea

Antineoplastic drug access in Thailand

Contact Info

Product

Resources

About